β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells

Zhu,Ting-Zhun; Li,Xiao-Ming; Luo,Li-Han; Song,Zhen-Quan; Gao,Xu; Li,Zhi-Qing; Su,Jing-Yuan; Liang,Guo-Biao

doi:10.3892/ijo.2014.2448

β-elemene inhibits stemness, promotes differentiation and impairs chemoresistance to temozolomide in glioblastoma stem-like cells

Authors:
- Ting-Zhun Zhu
- Xiao-Ming Li
- Li-Han Luo
- Zhen-Quan Song
- Xu Gao
- Zhi-Qing Li
- Jing-Yuan Su
- Guo-Biao Liang
View Affiliations

Affiliations: Department of Neurosurgery, General Hospital of Shenyang Military Area Command, Shenyang 110840, P.R. China, Health Care Centre, Shenyang Entry-Exit Inspection and Quarantine Bureau, Shenyang 110016, P.R. China
Published online on: May 19, 2014 https://doi.org/10.3892/ijo.2014.2448
Pages: 699-709

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accumulating evidence indicates that glioblastoma stem-like cells (GSCs) are key factors in tumour development, recurrence and chemoresistance. The impairment of stemness and the enhancement of differentiation contributes to the weakening of radiation and chemotherapy resistance of GSCs. We previously found that β-elemene was an effective anti-glioblastoma agent and chemosensitizer. In this study, we examined the distribution of CD133+ cells in human glioblastoma tissues by immunohistochemistry. Following treatment with β-elemene, the formation of GSC spheres was investigated by manual counting, the proliferation of GSCs was measured with a Cell Counting Kit-8 (CCK-8) assay, and the dispersion of GSC spheres was observed with an inverted microscope. GSC spheres were treated with β-elemene, and the expression levels of CD133, ATP-binding cassette subfamily G member 2 (ABCG2) and glial fibrillary acidic protein (GFAP) were examined by western blotting. After treatment with β-elemene, the volumes and weights of GSC xenografts were measured, and the expression of CD133, ABCG2 and GFAP was evaluated through immunohistochemistry analysis. After treatment with β-elemene and temozolomide (TMZ), GSC viability was examined by the CCK-8 assay, and the volumes and weights of xenografts were measured. We found that CD133+ cells were assembled in some vascular walls and also sparsely distributed in other parts of glioblastoma tissues. β-elemene decreased the formation of GSC spheres, dispersed GSC spheres and inhibited the proliferation of GSCs in vitro and in vivo. In the GSC spheres and xenografts treated with β-elemene, the expression of CD133 and ABCG2 was significantly downregulated, and the expression of GFAP increased. Furthermore, the sensitivity of GSCs to TMZ was enhanced in vitro and in vivo. These results suggest that β-elemene impaired the stemness of GSC spheres, promoted their differentiation and sensitized GSCs to TMZ. β-elemene will hopefully become a valuable agent to enhance the effects of radiotherapy and chemotherapy.

View Figures

View References

1	Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
2	Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 60:166–193. 2010.PubMed/NCBI
3	Omuro A and DeAngelis LM: Glioblastoma and other malignant gliomas: a clinical review. JAMA. 310:1842–1850. 2013. View Article : Google Scholar : PubMed/NCBI
4	Shah U and Morrison T: A review of the symptomatic management of malignant gliomas in adults. J Natl Compr Cancer Netw. 11:424–429. 2013.PubMed/NCBI
5	Eyüpoglu IY, Buchfelder M and Savaskan NE: Surgical resection of malignant gliomas-role in optimizing patient outcome. Nat Rev Neurol. 9:141–151. 2013.PubMed/NCBI
6	Grimm SA and Chamberlain MC: Brainstem glioma: a review. Curr Neurol Neurosci Rep. 13:3462013. View Article : Google Scholar : PubMed/NCBI
7	He J, Liu Y and Lubman DM: Targeting glioblastoma stem cells: cell surface markers. Curr Med Chem. 19:6050–6055. 2012. View Article : Google Scholar : PubMed/NCBI
8	Ding XW, Wu JH and Jiang CP: ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 86:631–637. 2010. View Article : Google Scholar : PubMed/NCBI
9	Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
10	Yuan X, Curtin J, Xiong Y, et al: Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 23:9392–9400. 2004. View Article : Google Scholar : PubMed/NCBI
11	Bidlingmaier S, Zhu X and Liu B: The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl). 86:1025–1032. 2008. View Article : Google Scholar : PubMed/NCBI
12	Beier D, Schulz JB and Beier CP: Chemoresistance of glioblastoma cancer stem cells - much more complex than expected. Mol Cancer. 10:1282011. View Article : Google Scholar : PubMed/NCBI
13	Liu G, Yuan X, Zeng Z, et al: Analysis of gene expression and chemoresistance of CD133⁺ cancer stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
14	Chen SL, You J and Wang GJ: Supercritical fluid extraction of β-elemene under lower pressure. Se Pu. 19:179–181. 2001.(In Chinese).
15	Zhang X, Zhang Y and Li Y: β-elemene decreases cell invasion by upregulating E-cadherin expression in MCF-7 human breast cancer cells. Oncol Rep. 30:745–750. 2013.
16	Bao F, Qiu J and Zhang H: Potential role of β-elemene on histone H1 in the H22 ascites hepatoma cell line. Mol Med Rep. 6:185–190. 2012.
17	Zhu T, Zhao Y, Zhang J, Li L, Zou L, Yao Y and Xu Y: β-Elemene inhibits proliferation of human glioblastoma cells and causes cell-cycle G0/G1 arrest via mutually compensatory activation of MKK3 and MKK6. Int J Oncol. 38:419–426. 2011.
18	Yao YQ, Ding X, Jia YC, Huang CX, Wang YZ and Xu YH: Anti-tumor effect of beta-elemene in glioblastoma cells depends on p38 MAPK activation. Cancer Lett. 264:127–134. 2008. View Article : Google Scholar : PubMed/NCBI
19	Zhu T, Xu Y, Dong B, Zhang J, Wei Z, Xu Y and Yao Y: β-elemene inhibits proliferation of human glioblastoma cells through the activation of gliamaturation factor β and induces sensitization to cisplatin. Oncol Rep. 26:405–413. 2011.
20	Yao YQ, Xu YH, Lu J, Zhou HY and Wang YZ: Effect of p38 MAPK on elemene-induced cell cycle arrest in C6 glioblastoma cells. Zhonghua Yi Xue Za Zhi. 88:56–58. 2008.(In Chinese).
21	Zhao YS, Zhu TZ, Yao YQ, et al: β-elemene inhibits Hsp90/Raf-1 molecular complex inducing apoptosis of glioblastoma cells. J Neurooncol. 107:307–314. 2012.
22	Zhang L and Zhang RH: Investigation of Tca8113 cell lines differentiation induced by β-elemene. J Oral Sci Res. 18:307–309. 2002.(In Chinese).
23	Fang Z, Chen HS, Chen HB and Liu YM: β-Elemene induced differentiation of PLA801D cell lines. Chin J Gerontol. 28:768–769. 2008.(In Chinese).
24	Wang HM, Yang XJ, Dong XT, et al: Correlation between the distribution of CD133-positive cells and the proliferation of microvessels in glioblastoma multiforme. Zhonghua Yi Xue Za Zhi. 91:781–785. 2011.(In Chinese).
25	He H, Niu CS and Li MW: Correlation between glioblastoma stem-like cells and tumor vascularization. Oncol Rep. 27:45–50. 2012.PubMed/NCBI
26	Carrasco-Garcia E, Sampron N, Aldaz P, et al: Therapeutic strategies targeting glioblastoma stem cells. Recent Pat Anticancer Drug Discov. 8:216–227. 2013. View Article : Google Scholar : PubMed/NCBI
27	Gal H, Makovitzki A, Amariglio N, Rechavi G, Ram Z and Givol D: A rapid assay for drug sensitivity of glioblastoma stem cells. Biochem Biophys Res Commun. 358:908–913. 2007. View Article : Google Scholar : PubMed/NCBI
28	Sampetrean O and Saya H: Characteristics of glioma stem cells. Brain Tumor Pathol. 30:209–214. 2013. View Article : Google Scholar
29	Salmaggi A, Boiardi A, Gelati M, et al: Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia. 54:850–860. 2006. View Article : Google Scholar
30	Choy W, Nagasawa DT, Trang A, Thill K, Spasic M and Yang I: CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme. Neurosurg Clin N Am. 23:391–405. 2012. View Article : Google Scholar : PubMed/NCBI
31	Zhang B, Sun J, Yu SP, et al: Rac1⁺ cells distributed in accordance with CD133⁺ cells in glioblastomas and the elevated invasiveness of CD133⁺ glioma cells with higher Rac1 activity. Chin Med J (Engl). 125:4344–4348. 2012.
32	Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821–5828. 2003.PubMed/NCBI
33	Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005. View Article : Google Scholar
34	Bleau AM, Huse JT and Holland EC: The ABCG2 resistance network of glioblastoma. Cell Cycle. 8:2936–2944. 2009. View Article : Google Scholar : PubMed/NCBI
35	Scharenberg CW, Harkey MA and Torok-Storb B: The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood. 99:507–512. 2002. View Article : Google Scholar : PubMed/NCBI
36	Nakanishi T and Ross DD: Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 31:73–99. 2012. View Article : Google Scholar : PubMed/NCBI
37	Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
38	Zhang L, Wu X, Xu T, Luo C, Qian J and Lu Y: Chemotherapy plus radiotherapy versus radiotherapy alone in patients with anaplastic glioma: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 139:719–726. 2013. View Article : Google Scholar : PubMed/NCBI
39	Hau P, Koch D, Hundsberger T, et al: Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology. 68:688–690. 2007. View Article : Google Scholar : PubMed/NCBI
40	Hart MG, Garside R, Rogers G, Stein K and Grant R: Temozolomide for high grade glioma. Cochrane Database Syst Rev. 4:CD0074152013.
41	Eramo A, Ricci-Vitiani L, Zeuner A, et al: Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 13:1238–1241. 2006. View Article : Google Scholar : PubMed/NCBI
42	Clement V, Sanchez P, de Tribolet N, Radovanovic I and Ruiz i Altaba A: HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol. 17:165–172. 2007. View Article : Google Scholar : PubMed/NCBI
43	Brada M, Judson I, Beale P, et al: Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer. 81:1022–1030. 1999. View Article : Google Scholar : PubMed/NCBI
44	Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA and Stupp R: Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 10:3728–3736. 2004. View Article : Google Scholar : PubMed/NCBI
45	Zhang H, Song N, Liu YP, Qu XJ, Hou KZ, Teng YE and Zhang JD: Reversal of resistance to adriamycin in human gastric cancer by β-elemene. J Chian Med Univ. 40:968–993. 2011.(In Chinese).
46	Li X, Wang G, Zhao J, et al: Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase. Cell Mol Life Sci. 62:894–904. 2005. View Article : Google Scholar : PubMed/NCBI
47	Tao L, Zhou L, Zheng LY and Yao M: Inhibition of eIF families expression and angiogenesis for human laryngeal carcinoma by elemene administration. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 40:840–845. 2005.(In Chinese).